OPRK1 and respiratory depression: Two compounds so identified demonstrated a dose-dependent antinociception three to five-times greater than morphine that was antagonized by mu- and/or kappa-opioid receptor-selective antagonists, and yet did not produce significant respiratory depression, hyperlocomotion, or conditioned place preference [49].